Andelyn Biosciences Announce New Chief Commercial Officer
(COLUMBUS, Ohio) – Andelyn Biosciences announces the appointment of Matt Niloff as Chief Commercial Officer (CCO). Niloff will lead the organization’s strategic marketing and business development activities to drive growth and expand business at the cell and gene therapy manufacturing company. He will assume the role of CCO on March 27th, 2023.
“The CCO role is vital to any CDMO’s success, and we knew that finding the right individual to lead this arm of our business was critical to continue our growth and expand our reach to serve the cell and gene therapy industry. The right individual to lead our growth is Matt Niloff. He brings tremendous talent and innovative ideas with him that will allow us the ability to provide More Treatments to More Patients. His 25 years of industry experience will elevate our strategy and position us for success. We particularly look forward to Matt joining our organization at this exciting time of growth and new initiatives as we open our new state-of-the-art manufacturing facility and corporate headquarters. We know Matt will add immense value to Andelyn,” said Wade Macedone, Chief Executive Officer of Andelyn Biosciences.
“I am very excited to join Andelyn and work with all of the incredible people and leaders who share my motivation to bring reliable manufacturing capability and capacity to the amazing companies and organizations developing and commercializing novel cell and gene therapies,” said Niloff. “I have always had a passion for enabling the biotechnology industry with manufacturing solutions that have real impact to advance life altering treatments and impact patients directly. I am excited to join the incredible team at Andelyn where I will leverage my commercial experience as we ready the company for meaningful growth in support of Andelyn’s clients seeking development and manufacturing strategies for their rapidly growing gene therapy pipelines.”
Niloff has over 25 years of experience in technical and commercial leadership roles. He specializes in driving rapid growth for companies enabling the biotech industry with innovative bioprocess manufacturing solutions. After beginning his career at the MIT Center for Genome Research working on the Human Genome Project, Niloff focused on driving the industry adoption of disruptive technologies at a variety of organizations including Millipore, Stedim, ATMI, and through acquisition, Sartorius, GE (now Cytiva), and for the last decade, Pall Corporation.
Prior to joining Andelyn, Niloff was a leader in Pall’s Integrated Solutions program where his team provided end-to-end manufacturing solutions and platforms, driving efficiency in the scale-up and manufacturing of gene therapy, protein therapeutic, and vaccine processes. He holds a Bachelor and Master of Science degrees in Biology from McGill University in Montreal, Canada.
With over 20 years of experience in clinical manufacturing, Andelyn’s scientific expertise has produced 450+ GMP clinical sublots in support of more than 75 worldwide clinical trials. Andelyn’s advanced quality systems, full regulatory support, and supply chain vertical integration are accelerating the development and manufacturing of innovative therapies to bring More Treatments to More Patients.
This Spring, Andelyn Biosciences will celebrate the grand opening its 185,000 sq. ft. manufacturing and corporate headquarters located in The Ohio State University, Carmenton Innovation District. Now operating in three facilities for plasmids, pre-clinical, and GMP clinical and commercial manufacturing, the opening of the new Andelyn Corporate Center completes a network of flexible and scalable sites that support end-to-end cell and gene therapy contract development and manufacturing.